The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: 2020-05-01

DOI: 10.1073/pnas.1920154117

Affiliations: 8

Authors: 17

Go to article
Institutions Share
UCLA Department of Radiation Oncology, United States of America (USA) 0.53
UCLA Jonsson Comprehensive Cancer Center (JCCC), United States of America (USA) 0.21
UCLA Department of Molecular, Cell, and Developmental Biology (MCDB), United States of America (USA) 0.06
UCLA Department of Microbiology, Immunology and Molecular Genetics (MIMG), United States of America (USA) 0.06
UCLA Department of Neurology, United States of America (USA) 0.06
UCLA Molecular Screening Shared Resource (MSSR), United States of America (USA) 0.03
UCLA Department of Neurosurgery, United States of America (USA) 0.03
UCLA Jane and Terry Semel Institute for Neuroscience and Human Behavior, United States of America (USA) 0.03

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER